

Second-tier Congenital Adrenal Hyperplasia (CAH) Proficiency Testing Program (PT)

Issued: February 2018

Introduction

This report is the Quarterly summary of CAHPT data reported within the specified data-reporting period for Quarter 1, 2018. Reports are distributed to all participants, state laboratory directors, and program colleagues by request. The tables within this report provide certification information for the proficiency testing (PT) specimen panel, statistical analysis of reported quantitative data, and the frequency distribution summaries for expected interpretations. An evaluation of your reported data is attached to this summary.

Certification of PT Specimens

The dried blood spot (DBS) PT specimens were prepared at 50% hematocrit, with different enrichments of five biomarkers for congenital adrenal hyperplasia (CAH); 17 α -hydroxyprogesterone (17OHP), 4-androstenedione (4AD), cortisol (Cort), 11-deoxycortisol (11D), 21-deoxycortisol (21D). Expected values (sum of endogenous and enrichment values) were determined by EIA (17OHP only) and LC-MS/MS. For determination of the Clinical Assessment (CA) NSQAP applies the formula: clinical ratio = $([17\text{OHP}] + [4\text{AD}])/[\text{CORT}]$. A cutoff of 1.0 is used to assess whether the specimen is Within Normal Limits (1) or Outside Normal Limits (2).

Table 1. Expected Values (ng/mL serum) and Expected Clinical Assessments (CA)

| Specimen | EIA | | LC-MS/MS | | | | | | |
|----------|-------|----|----------|------|-------|------|------|----------------|----|
| | 17OHP | CA | 17OHP | 4AD | Cort | 11D | 21D | Clinical Ratio | CA |
| 118A1 | 77.8 | 2 | 70.4 | 43.5 | 22.3 | 17.6 | 11.9 | 5.1 | 2 |
| 118A2 | 67.3 | 2 | 70.4 | 43.5 | 22.3 | 17.6 | 11.9 | 5.1 | 2 |
| 118A3 | 54.7 | 2 | 63.9 | 26.5 | 122.1 | 8.2 | 1.6 | 0.7 | 1 |
| 118A4 | 64.1 | 2 | 63.9 | 26.5 | 122.1 | 8.2 | 1.6 | 0.7 | 1 |
| 118A5 | 38.1 | 2 | 40.0 | 27.8 | 102.6 | 7.9 | 1.9 | 0.7 | 1 |

1 = Within Normal Limits 2 = Outside Normal Limits NE = Not Evaluated

Distribution of PT Specimens

On January 9, 2018, a PT panel of five DBS specimens was distributed six domestic laboratories and 28 international laboratories.

Participant Results

◆ Quantitative Data

We received data from 23 participants by the data reporting deadline. Laboratories were asked to report concentrations of 17OHP, 4AD, Cort, 11D and 21D analyzed by Second-tier tandem mass spectrometry (LC-MS/MS) and enzyme immunoassay (EIA) (optional). For the statistical summary analysis, we did not include data that were outside the 99% confidence interval.

All data are presented in units of ng/mL serum. Participants whose methods yield data in nM whole blood units were asked to multiply by the following factors for conversion to serum concentration: 0.66 (17OHP), 0.57 (4AD), 0.72 (CORT), and 0.69 (11D and 21D). Data that are not submitted in the requested units (ng/mL serum) are not accepted. Conversion factors are provided on the CAHPT Data Report Form.

Twenty-three laboratories reported results using LC-MS/MS. Fifteen of these labs also reported EIA results. The expected analyte concentration values were based on CDC expected values. Overall statistics from EIA (Table 2) and LC-MS/MS (Table 3) methods were combined so as to not identify an individual laboratory.

Table 2. Overall statistics—17OHP (ng/mL serum) by EIA

| Specimen | N | Mean | SD |
|----------|----|------|------|
| 118A1 | 14 | 64.8 | 14.1 |
| 118A2 | 15 | 66.3 | 9.3 |
| 118A3 | 15 | 60.2 | 13.2 |
| 118A4 | 14 | 58.0 | 11.0 |
| 118A5 | 15 | 37.5 | 6.0 |

Table 3. Overall statistics — 17OHP, 4AD, Cort, 11D, 21D (ng/mL serum) by LC-MS/MS

| Specimen | 17OHP | | | 4AD | | | Cort | | | 11D | | | 21D | | |
|----------|-------|------|-----|-----|-------|------|------|------|-----|-----|------|-----|-----|------|-----|
| | N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD |
| 118A1 | 23 | 41.0 | 8.6 | 23 | 19.1 | 3.2 | 16 | 18.3 | 4.5 | 16 | 13.4 | 4.5 | 22 | 5.6 | 1.5 |
| 118A2 | 23 | 42.1 | 9.7 | 23 | 19.8 | 2.9 | 16 | 19.0 | 4.2 | 16 | 13.6 | 4.7 | 22 | 5.7 | 1.5 |
| 118A3 | 23 | 27.7 | 6.4 | 23 | 134.3 | 18.0 | 16 | 8.0 | 4.3 | 13 | 1.3 | 1.5 | 22 | 1.3 | 2.9 |
| 118A4 | 23 | 27.3 | 5.8 | 23 | 133.3 | 18.1 | 16 | 8.0 | 4.4 | 13 | 1.4 | 1.5 | 22 | 1.2 | 2.7 |
| 118A5 | 23 | 27.2 | 5.5 | 23 | 112.6 | 15.6 | 16 | 8.6 | 4.3 | 13 | 0.9 | 1.1 | 22 | 0.9 | 1.7 |

◆ Qualitative Clinical Assessments

Qualitative assessments may differ by participant because of specific assessment practices. The frequency distribution of participants' Clinical Assessments for screening results is shown in Table 4.

Most programs use a clinical ratio to determine if samples are normal or abnormal. Samples with a calculated ratio less than the cutoff are considered "normal"; those samples with a calculated ratio greater than the cutoff are evaluated as "abnormal." LC-MS/MS cutoff values are summarized in Table 5.

Table 4. Frequency Distribution of Participants' Clinical Assessments (LC-MS/MS)

| Specimen | Within Normal Limits (WNL) | Outside Normal Limits (ONL) |
|----------|----------------------------|-----------------------------|
| 118A1 | 0 | 23 |
| 118A2 | 0 | 23 |
| 118A3 | 19 | 4 |
| 118A4 | 19 | 4 |
| 118A5 | 20 | 3 |

Table 5. LC-MS/MS Clinical Ratio Cutoff Values

| Specimen | All Laboratories | Domestic | International |
|----------|------------------|----------|---------------|
| MEAN | 1.96 | 1.10 | 2.15 |
| MODE | 1.00 | 1.00 | 2.50 |
| MIN | 0.10 | 1.00 | 0.10 |
| MAX | 9.00 | 1.40 | 9.00 |

Evaluations

Participants reported 11 False-positive results and no False-negative results based on the LC-MS/MS final Clinical Assessment.

Future Shipments

The Newborn Screening Quality Assurance Program will ship next quarter's PT specimens for CAHPT on July 10, 2018.

Direct Inquiries

If you have any comments or questions about CAHPT MS/MS analysis, contact Dr. Joanne V. Mei at 770-488-7945 or by e-mail at jvm0@cdc.gov

For data reporting questions, contact Irene Williams at nsqapdmt@cdc.gov

The content of this report may also be located on our website at:

http://www.cdc.gov/labstandards/nsqap_reports.html

**This program is co-sponsored by the Centers for Disease Control and Prevention (CDC) and
The Association of Public Health Laboratories (APHL)**

NEWBORN SCREENING QUALITY ASSURANCE PROGRAM

Direct inquiries to:

Centers for Disease Control and Prevention
4770 Buford Highway NE, MS/F19
Atlanta, GA 30341-3724
Phone: 404-488-7945 Email: jvm0@cdc.gov

Editors

Joanne Mei
Irene Williams

